{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:10:40Z","timestamp":1790637040356,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.drudis.2018.02.012","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T15:10:46Z","timestamp":1519917046000},"page":"1175-1182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts"],"prefix":"10.1016","volume":"23","author":[{"given":"Ping-Pin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan M.","family":"Kros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2018.02.012_bib0005","series-title":"Prescribing Information (Kymriah\u2122)","author":"Novartis","year":"2017"},{"key":"10.1016\/j.drudis.2018.02.012_bib0010","series-title":"Prescribing Information","author":"Yescarta\u2122","year":"2017"},{"key":"10.1016\/j.drudis.2018.02.012_bib0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2017.12.002","article-title":"CD19 CAR T cells","volume":"171","author":"Sadelain","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2018.02.012_bib0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1377\/hlthaff.26.3.647","article-title":"Balancing modern medical benefits and risks","volume":"26","author":"Juhn","year":"2007","journal-title":"Health Aff."},{"key":"10.1016\/j.drudis.2018.02.012_bib0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/med.21463","article-title":"Breakthroughs in modern cancer therapy and elusive cardiotoxicity: critical research-practice gaps, challenges, and insights","volume":"38","author":"Zheng","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2018.02.012_bib0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.drudis.2018.02.012_bib0035","unstructured":"FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novartis Pharmaceuticals Corporation."},{"key":"10.1016\/j.drudis.2018.02.012_bib0040","series-title":"With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.drudis.2018.02.012_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/annonc\/mdw615","article-title":"Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance","volume":"28","author":"Bonavida","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0050","series-title":"Summary Basis for Regulatory Action","author":"Lu","year":"2017"},{"key":"10.1016\/j.drudis.2018.02.012_bib0055","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2018.02.012_bib0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2018.02.012_bib0065","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2018.02.012_bib0070","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","article-title":"Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells","volume":"128","author":"Faitschuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.02.012_bib0075","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.02.012_bib0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Almasbak","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2018.02.012_bib0085","doi-asserted-by":"crossref","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2018.02.012_bib0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2018.02.012_bib0095","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.3390\/cancers8030036","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","volume":"8","author":"Golubovskaya","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2018.02.012_bib0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.drudis.2018.02.012_bib0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2018.02.012_bib0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2018.02.012_bib0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25 years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev."},{"key":"10.1016\/j.drudis.2018.02.012_bib0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MOH.0000000000000182","article-title":"Paving the road ahead for CD19 CAR T-cell therapy","volume":"22","author":"Nellan","year":"2015","journal-title":"Curr. Opin. Hematol."},{"issue":"Suppl","key":"10.1016\/j.drudis.2018.02.012_bib0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0135","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2018.02.012_bib0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","article-title":"Development of CAR T cells designed to improve antitumor efficacy and safety","volume":"178","author":"Jaspers","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2018.02.012_bib0145","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1189\/jlb.5RU0817-315R","article-title":"Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy","volume":"102","author":"Wang","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0150","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming antigen escape with CAR T-cell therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drudis.2018.02.012_bib0155","first-page":"403","article-title":"CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphomas","volume":"6","author":"Onea","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.drudis.2018.02.012_bib0160","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-3143","article-title":"Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure","volume":"75","author":"Sotillo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2018.02.012_bib0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-017-0070-9","article-title":"Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory\/relapsed acute lymphoblastic leukemia","volume":"6","author":"Wei","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0170","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.1005802107","article-title":"Mixed T cell receptor dimers harbor potentially harmful neoreactivity","volume":"107","author":"van Loenen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2018.02.012_bib0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2018.02.012_bib0180","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2018.02.012_bib0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cell subsets for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0195","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.02.012_bib0200","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood\u2013brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2018.02.012_bib0205","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2018.02.012_bib0210","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/bloodadvances.2016000034","article-title":"Immunotherapy for acute lymphoblastic leukemia: from famine to feast","volume":"1","author":"Davis","year":"2016","journal-title":"Blood Advances"},{"key":"10.1016\/j.drudis.2018.02.012_bib0215","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2009.264","article-title":"Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985\u20132001","volume":"24","author":"Krishnan","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.02.012_bib0220","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2017.165142","article-title":"Acute lymphoblastic leukemia of the central nervous system: on the role of PBX1","volume":"102","author":"Alsadeq","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2018.02.012_bib0225","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2003.04.096","article-title":"Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture","volume":"21","author":"Burger","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0230","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.02.012_bib0235","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.02.012_bib0240","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.02.012_bib0245","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2018.02.012_bib0250","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0255","series-title":"Principles and Practice of Pediatric Oncology","year":"2015"},{"key":"10.1016\/j.drudis.2018.02.012_bib0260","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0265","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drudis.2018.02.012_bib0270","series-title":"Prescribing Information","author":"Tocilizumab","year":"2010"},{"key":"10.1016\/j.drudis.2018.02.012_bib0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.02.012_bib0280","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2018.02.012_bib0285","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2014-08-591875","article-title":"Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia","volume":"124","author":"Kaur","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.02.012_bib0290","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2018.02.012_bib0295","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2018.02.012_bib0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/08830185.2017.1365146","article-title":"Damage-associated molecular patterns and their role as initiators of inflammatory and auto-immune signals in systemic lupus erythematosus","volume":"36","author":"Alvarez","year":"2017","journal-title":"Int. Rev. Immunol ."},{"key":"10.1016\/j.drudis.2018.02.012_bib0305","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nri.2017.9","article-title":"Dying cells actively regulate adaptive immune responses","volume":"17","author":"Yatim","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2018.02.012_bib0310","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jmp\/20.4.403","article-title":"\u201cPlaying God\u201d and the removal of life-prolonging therapy","volume":"20","author":"Paris","year":"1995","journal-title":"J. Med. Philos."},{"key":"10.1016\/j.drudis.2018.02.012_bib0315","first-page":"401","article-title":"Physician responsibility for patients\u2019 quality of life","volume":"10","author":"Rosoff","year":"2008","journal-title":"Virtual Mentor"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461730569X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461730569X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:34:25Z","timestamp":1761222865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964461730569X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S135964461730569X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2018.02.012","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2018.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}